☆ 4.6 Letter

Response to Physiologically Based Pharmacokinetic Modeling at the Extremes of Age

CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)

获取全文
添加到收藏夹

期刊

CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 93, 期 2, 页码 149-149

出版社

WILEY
DOI: 10.1038/clpt.2012.200

关键词

-

类别

Pharmacology & Pharmacy

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Medicinal

X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor

Souvik Banerjee, Foyez Mahmud, Shanshan Deng, Lingling Ma, Mi-Kyung Yun, Sayo O. Fakayode, Kinsie E. Arnst, Lei Yang, Hao Chen, Zhongzhi Wu, Pradeep B. Lukka, Keyur Parmar, Bernd Meibohm, Stephen W. White, Yuxi Wang, Wei Li, Duane D. Miller

Summary: Small molecules targeting the colchicine binding site on tubulin have shown therapeutic efficacy in treating various cancers. The synthesized analogues of pyridopyrimidine and hydroquinoxalinone compounds demonstrated improved metabolic stability and strong antiproliferative effects on human cancer cell lines. In vivo studies showed that two analogues, 5m and 5t, significantly inhibited tumor growth and metastasis in a paclitaxel-resistant xenograft model.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹
Article Chemistry, Medicinal

Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis

Mercedes Gonzalez-Juarrero, Pradeep B. Lukka, Santosh Wagh, Amanda Walz, Jennifer Arab, Camron Pearce, Zohaib Ali, Josiah T. Ryman, Keyur Parmar, Zaid Temrikar, Juan Munoz-Gutierrez, Gregory T. Robertson, Jiuyu Liu, Anne J. Lenaerts, Charles Daley, Richard E. Lee, Miriam Braunstein, Anthony J. Hickey, Bernd Meibohm

Summary: Spectinamide-1599 shows promise as an inhalational therapy candidate, with significant efficacy and good tolerability in a murine TB model. Compared to oral or intravenous administration, intrapulmonary delivery increases lung exposure and demonstrates superior efficacy.

ACS INFECTIOUS DISEASES (2021)

添加到收藏夹
Article Pharmacology & Pharmacy

Knowledge Gaps in the Pharmacokinetics of Therapeutic Proteins in Pediatric Patients

Bernd Meibohm

Summary: Therapeutic proteins such as monoclonal antibodies and hormone analogs are increasingly important in pediatric pharmacotherapy, but there are knowledge gaps in understanding the processes governing their disposition in children. The article highlights three receptor systems as examples and emphasizes the priority of addressing these gaps for the development of pediatric drugs nationally and globally.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹
Article Oncology

Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer

Shanshan Deng, Raisa I. Krutilina, Kelli L. Hartman, Hao Chen, Deanna N. Parke, Rui Wang, Foyez Mahmud, Dejian Ma, Pradeep B. Lukka, Bernd Meibohm, Tiffany N. Seagroves, Duane D. Miller, Wei Li

Summary: The study demonstrates the potential of CH-2-77 as a promising tubulin inhibitor for the treatment of triple-negative breast cancer. CH-2-77 inhibits cancer cell proliferation, disrupts microtubule assembly, and induces cell apoptosis. In vivo experiments show that CH-2-77 effectively suppresses tumor growth and prevents lung metastasis. These findings highlight the importance of further developing CH-2-77 as an anticancer agent.

MOLECULAR CANCER THERAPEUTICS (2022)

添加到收藏夹
Article Pharmacology & Pharmacy

Moving Toward a Question-Centric Approach for Regulatory Decision Making in the Context of Drug Assessment

Flora T. Musuamba, S. Y. Amy Cheung, Pieter Colin, Elin H. Davies, Jeffrey S. Barret, Francesco Pappalardo, Michael Chappell, Jean-Michel Dogne, Adriana Ceci, Oscar Della Pasqua, Ine S. Rusten

Summary: The benefit/risk balance is the most important question when considering market access for medicinal products. This assessment involves evaluating efficacy, safety, dose selection, pharmacology, and drug quality. However, there is currently no systematic approach to assess and establish the acceptability of alternative methods and data sources, leading to regulatory skepticism toward new data types and methods. To mitigate uncertainties in efficacy and safety characterization, a data-knowledge backbone is needed. This white paper proposes an ecosystem based on a repository, high-quality standards, and credibility assessment for better regulatory decision making.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹
Review Pharmacology & Pharmacy

Clinical and Translational Pharmacology Considerations for Anti-infectives Approved Under the FDA Animal Rule

Zaid H. Temrikar, Jennifer E. Golden, Colleen B. Jonsson, Bernd Meibohm

Summary: The US FDA's Animal Rule provides a pathway for drug approval in serious or life-threatening conditions where traditional clinical trials are not feasible. This review discusses the challenges in translating data from in vitro and animal models to human dosing for antimicrobials.

CLINICAL PHARMACOKINETICS (2023)

添加到收藏夹
Article Pharmacology & Pharmacy

Opportunities for Systems Biology and Quantitative Systems Pharmacology to Address Knowledge Gaps for Drug Development in Pregnancy

Jeffrey S. Barrett, Karim Azer

Summary: Pregnant women are neglected as participants in clinical trials and targeted drug research, despite the need for pharmacotherapy during pregnancy. The uncertain risk potential and the lack of timely toxicology and developmental pharmacology studies contribute to this challenge. Even when clinical trials are conducted in pregnant women, they often lack power and exclude evaluation across multiple stages of pregnancy. The development of quantitative systems pharmacology models could fill these knowledge gaps and improve risk assessment and trial design. Rating: 8/10

JOURNAL OF CLINICAL PHARMACOLOGY (2023)

添加到收藏夹
Review Pharmacology & Pharmacy

The future of rare disease drug development: the rare disease cures accelerator data analytics platform (RDCA-DAP)

Jeffrey S. Barrett, Alexandre Betourne, Ramona L. Walls, Kara Lasater, Scott Russell, Amanda Borens, Shlok Rohatagi, Will Roddy

Summary: Rare disease drug development faces challenges in accessing limited data, with data sharing not guaranteed in the rare disease ecosystem. Pharmaceutical sponsors initiate data landscaping efforts to find informative sources on disease prevalence, patient selection, disease progression, and likelihood of patient response to therapy. Rare disease drug development relies on increased data sharing and collaboration, and initiatives like the RDCA-DAP aim to improve the quality of regulatory applications for rare disease treatments.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2023)

添加到收藏夹
Article Immunology

Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes

Zaid H. Temrikar, Sunitha Kodidela, Santosh Kumar, Jiuyu Liu, Gregory T. Robertson, Richard E. Lee, Anthony J. Hickey, Mercedes Gonzalez-Juarrero, Bernd Meibohm

Summary: Spectinamides are a novel series of spectinomycin analogs being developed for the treatment of tuberculosis. Spectinamide 1599, the preclinical lead, shows strong efficacy against tuberculosis with good pharmacokinetic properties and excellent safety profiles. It is more effective against log phase bacteria compared to other resistant forms, similar to the established antituberculosis drug isoniazid.

TUBERCULOSIS (2023)

添加到收藏夹
Article Pharmacology & Pharmacy

Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics

Keyur R. Parmar, Pradeep B. Lukka, Santosh Wagh, Zaid H. Temrikar, Jiuyu Liu, Richard E. Lee, Miriam Braunstein, Anthony J. Hickey, Gregory T. Robertson, Mercedes Gonzalez-Juarrero, Andrea Edginton, Bernd Meibohm

Summary: Spectinamides 1599 and 1810 are being developed as potential treatments for multidrug-resistant and extensively drug-resistant tuberculosis. A physiologically based pharmacokinetic (PBPK) model has been developed to predict the pharmacokinetics of these compounds in various tissues, including those relevant to tuberculosis infection. The model accurately predicts the drug exposure in mice and rats, and can be used to optimize the dosing regimens.

PHARMACEUTICS (2023)

添加到收藏夹
Article Pharmacology & Pharmacy

Barriers to global pharmacometrics: educational challenges and opportunities across the globe

Robin Michelet, Linda B. S. Aulin, Jens M. M. Borghardt, Teresa Dalla Costa, Paolo Denti, Manuel Ibarra, Guangda Ma, Bernd Meibohm, Goonaseelan (Colin) Pillai, Stephan Schmidt, Stefanie Hennig, Charlotte Kloft

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2023)

添加到收藏夹
Article Chemistry, Medicinal

Novel, Brain-Permeable, Cross-Species Benzothiazole Inhibitors of Microsomal Prostaglandin E Synthase-1 (mPGES-1) Dampen Neuroinflammation In Vitro and In Vivo

Madison N. Sluter, Rajib Bhuniya, Xinrui Yuan, Andhavaram Ramaraju, Yu Chen, Ying Yu, Keyur R. Parmar, Zaid H. Temrikar, Ashish Srivastava, Bernd Meibohm, Jianxiong Jiang, Chao-Yie Yang

Summary: Our findings showed that our thiazole-based mPGES-1 inhibitors, UT-11 and compound 19, were able to suppress PGE2 production in human and murine cells. We selected UT-11 for evaluation in a lipopolysaccharide (LPS)-induced inflammation model based on in vitro and in vivo pharmacokinetic data. Our compound significantly suppressed proinflammatory cytokines and chemokines in the hippocampus, indicating its potential in treating neuroinflammatory conditions.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2023)

添加到收藏夹
Article Chemistry, Medicinal

Design, Synthesis, and Biological Evaluation of Pyrimidine Dihydroquinoxalinone Derivatives as Tubulin Colchicine Site-Binding Agents That Displayed Potent Anticancer Activity Both In Vitro and In Vivo

Satyanarayana Pochampally, Kelli L. Hartman, Rui Wang, Jiaxing Wang, Mi-Kyung Yun, Keyur Parmar, Hyunseo Park, Bernd Meibohm, Stephen W. White, Wei Li, Duane D. Miller

Summary: A new compound that inhibits cancer cell proliferation has been discovered and shows high anticancer activity and a long half-life. It exhibits significant potency against a wide range of cancer cell lines and has the potential for further preclinical evaluation as a candidate for development.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2023)

添加到收藏夹
Editorial Material Pharmacology & Pharmacy

An AI Approach to Generating MIDD Assets Across the Drug Development Continuum

Jeffrey S. Barrett, Rahul K. Goyal, Jogarao Gobburu, Szczepan Baran, Jyotika Varshney

Summary: Model-informed drug development involves using models derived from preclinical and clinical data to inform drug development and decision-making. Traditional approaches rely on internal data stores and structural models, while an AI/ML-based approach relies on diverse data sources and past successes/failures to make more informed decisions. This approach has the potential to transform regulatory science, optimize information value, and increase confidence in drug safety and efficacy.

AAPS JOURNAL (2023)

添加到收藏夹
Article Chemistry, Medicinal

Design, Synthesis, and Biological Evaluation of Pyrimidine Dihydroquinoxalinone Derivatives as Tubulin Colchicine Site- Binding Agents That Displayed Potent Anticancer Activity Both In Vitro and In Vivo

Satyanarayana Pochampally, Kelli L. Hartman, Rui Wang, Jiaxing Wang, Mi-Kyung Yun, Keyur Parmar, Hyunseo Park, Bernd Meibohm, Stephen W. White, Wei Li, Duane D. Miller

Summary: By modifying the pyrimidine dihydroquinoxalinone scaffold, we discovered a new tubulin-polymerization inhibitor, compound 12k, that exhibited potent anticancer activity and significant tumor growth inhibition in vivo.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2023)

添加到收藏夹
暂无数据
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.